After treatment with immunotherapies, up to 40% of patients with both LGI1 and CASPR2 antibody encephalitis experience relapses (11, 13) and residual neurocognitive impairments, which affect quality of life and lead to disability (14, 15). Here, CNTNAP2 is linked to viral encephalitis.